SCHEMBL2475422

SCHEMBL2475422

CCCn1c(C(=O)OCC)c(C)c2ccnc(N(Cc3ccc(F)cc3C)C(=O)OC(C)(C)C)c21

nearest known ligand 0.33

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 3/20 0.33
HTR2C P28335 1/20 0.33
SLC6A4 P31645 1/20 0.33
KDM5A P29375 1/20 0.33
KDM4C Q9H3R0 1/20 0.33
KDM5B Q9UGL1 1/20 0.33
TP53 P04637 1/20 0.32
MAPT P10636 1/20 0.32
TSHR P16473 1/20 0.31
GABRG2 P18507 1/20 0.31
GABRB3 P28472 1/20 0.31
GABRA5 P31644 1/20 0.31
CPB2 Q96IY4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2473584 0.87 HTR2C (0.33) HTR2AHTR2CSLC6A4KDM5AKDM4C
SCHEMBL2479063 0.79 KMT2A (0.36) KDM5AKDM4CKDM5BTP53MAPT
SCHEMBL2473102 0.71 CCNT1 (0.35) HTR2AHTR2CSLC6A4KDM5AKDM4C
SCHEMBL5430886 0.69 ABL1 (0.37) GABRG2GABRB3GABRA5
SCHEMBL2475870 0.68 MCL1 (0.37) HTR2CSLC6A4
SCHEMBL5439596 0.68 FBP1 (0.33) KDM5AKDM4CKDM5BMAPT
SCHEMBL2475151 0.68 MAPT (0.30) MAPT
SCHEMBL5439591 0.68 FBP1 (0.33) KDM5AKDM4CKDM5BMAPT
Potassium Ion SCHEMBL2477023 0.68 FBP1 (0.33) MAPTCPB2
SCHEMBL5439602 0.68 FBP1 (0.33) KDM5AKDM4CKDM5BMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1787991-B2 PYRROLO[2,3-c]PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE TAKEDA PHARMACEUTICALS CO (JP) 2020-06-24 EP disclosed
US-20180148446-A1 PYRROLO [2,3-c] PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE TAKEDA PHARMACEUTICALS CO (JP) 2018-05-31 US disclosed
EP-1787991-B1 PYRROLO[2,3-c]PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE TAKEDA PHARMACEUTICAL (JP) 2011-10-05 EP disclosed
US-20070293532-A1 Pyrrolo [2,3-C] Pyridine Compound, Process for Producing the Same, and Use TAKEDA PHARMACEUTICAL COMPAN6Y LIMITED (JP) 2007-12-20 US disclosed
EP-1787991-A1 PYRROLOÝ2,3-c¨PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Pharmaceutical Company Limited (JP) 2007-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148446-A1 PYRROLO [2,3-c] PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE PGA5, ATP6AP1, PPA1 HTR2A 3280/4885HTR2C 2307/4885SLC6A4 4269/4885
US-20070293532-A1 Pyrrolo [2,3-C] Pyridine Compound, Process for Producing the Same, and Use PGA5, ATP6AP1, PPA1 HTR2A 3280/4885HTR2C 2307/4885SLC6A4 4269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.